US FDA News: FDA Approves New Treatment for Pompe Disease

Today the FDA approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
Read more: FDA Approves New Treatment for Pompe Disease